Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bafna PharmaceuticalsNSE:BAFNAPH +2.00%60 Debt-to-EBITDA is 1.76 as of Mar. 2026, which is 42% above its 10-year median of 1.24. GuruFocus rates NSE:BAFNAPH with a GF Score™ of 60/100 and a GF Value™ of ₹91.13 (Significantly Overvalued). The stock has 9 warning signs investors should review. Among 690 Drug Manufacturers companies, Bafna Pharmaceuticals ranks worse than 52.17% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bafna Pharmaceuticals's Debt-to-EBITDA or its related term are showing as below:
NSE:BAFNAPH'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -16.17 Med: 1.24 Max: 2.4
Current: 1.81
During the past 13 years, the highest Debt-to-EBITDA Ratio of Bafna Pharmaceuticals was 2.40. The lowest was -16.17. And the median was 1.24.
NSE:BAFNAPH's Debt-to-EBITDA is ranked worse than 52.17% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs NSE:BAFNAPH: 1.81
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bafna Pharmaceuticals Debt-to-EBITDA Related Terms
Bafna Pharmaceuticals Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bafna Pharmaceuticals's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:BAFNAPH vs ZTS, UTHR: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Bafna Pharmaceuticals's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bafna Pharmaceuticals Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Bafna Pharmaceuticals's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bafna Pharmaceuticals's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Bafna Pharmaceuticals (NSE:BAFNAPH) has a Debt-to-EBITDA of 1.76 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bafna Pharmaceuticals. This is 42% above median its historical median of 1.24. According to the industry distribution chart, Bafna Pharmaceuticals ranks #360 out of 690 companies in the Drug Manufacturers industry, placing it in the top 52.2%.
Is Bafna Pharmaceuticals' Debt-to-EBITDA too high?
Bafna Pharmaceuticals' current Debt-to-EBITDA of 1.76 is 42% above median its 10-year median of 1.24. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Bafna Pharmaceuticals' value of 1.76 is 5.4% above this industry median. Based on the distribution chart, Bafna Pharmaceuticals ranks #360 out of 690 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Bafna Pharmaceuticals has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Bafna Pharmaceuticals' Debt-to-EBITDA compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bafna Pharmaceuticals ranks #360 out of 690 companies for Debt-to-EBITDA. This places Bafna Pharmaceuticals in the lower half of its industry. The industry median Debt-to-EBITDA is 1.67. Bafna Pharmaceuticals' value of 1.76 is 5.4% above this benchmark. While the company's 10-year median is 1.24 vs. the industry median of 1.67, Bafna Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bafna Pharmaceuticals's current Debt-to-EBITDA of 1.76 is 5.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bafna Pharmaceuticals. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bafna Pharmaceuticals's current Debt-to-EBITDA is 1.76, which is 42% above median its own 10-year median of 1.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bafna Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Bafna Pharmaceuticals (NSE:BAFNAPH) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹91.13, compared to a current price of ₹233.58 — trading 156.3% above its estimated fair value. The current Debt-to-EBITDA is 1.76, which is 42% above median its 10-year median of 1.24 and 5.4% above the Drug Manufacturers industry median of 1.67. Bafna Pharmaceuticals' overall GF Score™ is 60/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bafna Pharmaceuticals (NSE:BAFNAPH), the current Debt-to-EBITDA is 1.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bafna Pharmaceuticals (NSE:BAFNAPH) Overvalued in 2026?
Based on GuruFocus' analysis, Bafna Pharmaceuticals stock appears to be overvalued.
The current stock price of ₹233.58 is trading 156.3% above its estimated GF Value™ of ₹91.13.
GuruFocus considers Bafna Pharmaceuticals to be Significantly Overvalued.
Key valuation signals for NSE:BAFNAPH:
Debt-to-EBITDA: 1.76 (42% above median its 10-year median of 1.24)
GF Value™: ₹91.13 vs. price of ₹233.58 (156.3% above fair value)
Industry Position: 5.4% above the Drug Manufacturers median (#360 of 690)
No single metric tells the full story. See the NSE:BAFNAPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bafna Pharmaceuticals Ltd is an Indian pharmaceutical company mainly offering Contract Research and Manufacturing (CRAMS), Technology Transfers, Formulation, and Analytical Development services. It is engaged in the business of manufacturing finished pharmaceutical formulations, specializing in non-betalactam solid oral dosage forms, besides other emerging and potential products and forms in various therapeutic areas such as cardiology, lifestyle and potent drugs, and pain management. The company delivers generic pharmaceutical products for the UK, Australia, the EU, and emerging markets. In addition, it has launched its own brands in Sri Lanka, the Philippines, Tanzania, and Nigeria, offering products for some high-demand therapies like diabetes, cardiovascular, and oncology.
60GF Score
Get the complete analysis for NSE:BAFNAPH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BAFNAPH has been successfully added to your 
